FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease


You May Also Like

National Rheumatology and Psoriasis Organizations Release Joint Guideline for Treating Psoriatic Arthritis

Recommends Treat-to-Target Approach, First-Line Use of TNFi Biologics, and Smoking CessationAtlanta, Dec. 03, 2018 ...

Zomedica Provides Product Development Update

ANN ARBOR, Mich., June 19, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) ...